Keystone Symposia

This meeting took place in 2012

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Nucleic Acid Therapeutics: From Base Pairs to Bedsides (A2)

Organizer(s) Alan M. Gewirtz (in memoriam), Anastasia Khvorova and Mark A. Kay
January 10—15, 2012
Eldorado Hotel & Spa • Santa Fe, NM USA
Abstract Deadline: Sep 15, 2011
Late Abstract Deadline: Oct 13, 2011
Scholarship Deadline: Sep 15, 2011
Early Registration Deadline: Nov 10, 2011

Sponsored by Isis Pharmaceuticals, Inc. and Regulus Therapeutics Inc.

Summary of Meeting:
Small molecules and antibodies have revolutionized the treatment of cancer and appear promising for the treatment of many other diseases as well. Nonetheless, there are many candidate therapeutic targets that are not amenable to attack by the current generation of targeted therapies and, in a small but growing number of patients, resistance to initially successful targeted treatments evolves. This symposium will focus on the medicinal promise of pre- and post- transcriptional gene silencing (PPTGS) using oligodeoxynucleotides, small interfering RNA, microRNA and other nucleic acid based molecules. The meeting is motivated by the hypothesis that these molecules can be developed into effective drugs for the treatment of many common diseases that are collectively responsible for a great deal of human suffering. As this symposium will highlight, there is still much to do, but many in the field now hope that the time has finally arrived when “antisense” therapies will finally come of age and fulfill their promise as the magic bullets of the 21st century.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Veenu Aishwarya
AUM LifeTech, USA

Dongbo Yu
University of Texas Southwestern Medical Center, USA